BioNTech SE (BNTX) Cost of Revenue (2018 - 2026)

BioNTech SE has reported Cost of Revenue for 8 years, with the latest figure at $388.0 million in Q4 2025.

• Quarterly Cost of Revenue rose 49.11% year-over-year to $388.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $736.0 million (up 25.75% YoY) and the FY2025 annual result came in at $725.1 million, up 25.36% from the prior year.
• Cost of Revenue climbed to $388.0 million in Q4 2025 per BNTX's latest filing, from $173.4 million in the prior quarter.
• Over five years, Cost of Revenue peaked at $1.5 billion in Q1 2022 and troughed at $1428.6 in Q3 2021.
• A 5-year average of $359.9 million and a median of $190.0 million in 2023 frame the typical range for Cost of Revenue.
• The widest YoY moves for Cost of Revenue: up 4316954798549969.5% in 2021, down 100.0% in 2021.
• Over 5 years, Cost of Revenue stood at $667.2 million in 2021, then sank by 71.94% to $187.2 million in 2022, then increased by 2.93% to $192.7 million in 2023, then jumped by 35.03% to $260.2 million in 2024, then jumped by 49.11% to $388.0 million in 2025.
• According to Business Quant data, Cost of Revenue over the past three periods registered $388.0 million, $173.4 million, and $86.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.